日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Two years efficacy and safety outcomes of using allogeneic, pooled mesenchymal stromal cells for osteoarthritis of knee in a double-blind randomized placebo-controlled phase 3 study

一项双盲随机安慰剂对照的3期研究评估了使用异体混合间充质干细胞治疗膝骨关节炎的两年疗效和安全性结果。

期刊:Osteoarthritis and Cartilage Open
影响因子:2.8
doi:10.1016/j.ocarto.2025.100723
Gupta, Pawan Kumar; Maheshwari, Sunil; Cherian, Joe Joseph; Goni, Vijay; Sharma, Arun Kumar; Tripathy, Sujit Kumar; Talari, Keerthi; Pandey, Vivek; Sancheti, Parag Kantilal; Singh, Saurabh; Bandyopadhyay, Syamasis; Shetty, Naresh; Kamath, Surendra Umesh; Prahaldbhai, Purohit Sharad; Abraham, Jijy; Kannan, Suresh; Verma, Nikhil N; Kumar, Uday
关节炎
发育与干细胞
干细胞
细胞生物学
发表日期：2026
文献求助 收藏

Label extension, single-arm, phase III study shows efficacy and safety of stempeucel® in patients with critical limb ischemia due to atherosclerotic peripheral arterial disease

标签扩展、单臂、III期研究表明，stempeucel® 对因动脉粥样硬化性外周动脉疾病引起的严重肢体缺血患者有效且安全。

期刊:Stem Cell Research & Therapy
影响因子:7.3
doi:10.1186/s13287-023-03292-w
Gupta, Pawan Kumar; Shivashankar, P; Rajkumar, M; Mahapatra, Subhendu S; Desai, Sanjay C; Dhar, Anita; Krishna, Vinay; Raviraja, N S; Bhat, Samatha; Viswanathan, Pachaiyappan; Kannan, Suresh; Abraham, Jijy; Boggarapu, Hema; Manjuprasad, M S; Udaykumar, K
心血管
动脉粥样硬化
发表日期：2023
文献求助 收藏

Phase IV postmarketing surveillance study shows continued efficacy and safety of Stempeucel in patients with critical limb ischemia due to Buerger's disease.

IV 期上市后监测研究表明，Stempeucel 对因布尔格氏病引起的严重肢体缺血患者持续有效且安全

期刊:Stem Cells Translational Medicine
影响因子:4.9
doi:10.1002/sctm.21-0197
Gupta Pawan Kumar, Dutta Santanu, Kala Sanjay, Nekkanti Muralikrishna, Desai Sanjay C, Mahapatra Subhendu S, Dhar Anita, Raju Radhakrishnan, M Rajkumar, Behera Arunanshu, P Shivashankar, Raviraja N S, Viswanathan Pachaiyappan, Chandrashekar Mithun, Thej Charan, K V Prasanth, Abraham Jijy, Boggarapu Hema, Udaykumar K
其它
发表日期：2021
文献求助 收藏